Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Population-based study of screening test performance indices of three human papillomavirus DNA tests

Wahlström, Cecilia LU ; Iftner, Thomas ; Dillner, Joakim LU and Dillner, Lena LU (2007) In Journal of Medical Virology 79(8). p.1169-1175
Abstract
In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical... (More)
In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical intraepithelial neoplasia grade 2 or worse (CINII+), and absolute risk of CINII+ was 7.1%, 87.1%, and 23.2% for AmpliTaq GP5+/6+ PCR, 11.9%, 88.9%, and 11.0% for AmpliTaq Gold GP5+/6+ PCR, 15.7%, 93.4%, and 9.8% for Amplicor, 10.0%, 92.9%, and 15.3% for Amplicor with raised cut-off, and 7.8%, 79.7%, and 16.9% for Hybrid Capture II. In conclusion, AmpliTaq GP5+/6+ PCR and Amplicor with raised cut-off value have adequate performance indices for primary screening. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
longitudinal cohort study, cervical cancer, PCR
in
Journal of Medical Virology
volume
79
issue
8
pages
1169 - 1175
publisher
John Wiley & Sons Inc.
external identifiers
  • wos:000247642200018
  • scopus:34347334426
  • pmid:17596834
ISSN
1096-9071
DOI
10.1002/jmv.20898
language
English
LU publication?
yes
id
cc555a40-3beb-4cdc-bb91-77479738d504 (old id 646388)
date added to LUP
2016-04-01 12:15:13
date last changed
2022-01-27 01:06:22
@article{cc555a40-3beb-4cdc-bb91-77479738d504,
  abstract     = {{In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical intraepithelial neoplasia grade 2 or worse (CINII+), and absolute risk of CINII+ was 7.1%, 87.1%, and 23.2% for AmpliTaq GP5+/6+ PCR, 11.9%, 88.9%, and 11.0% for AmpliTaq Gold GP5+/6+ PCR, 15.7%, 93.4%, and 9.8% for Amplicor, 10.0%, 92.9%, and 15.3% for Amplicor with raised cut-off, and 7.8%, 79.7%, and 16.9% for Hybrid Capture II. In conclusion, AmpliTaq GP5+/6+ PCR and Amplicor with raised cut-off value have adequate performance indices for primary screening.}},
  author       = {{Wahlström, Cecilia and Iftner, Thomas and Dillner, Joakim and Dillner, Lena}},
  issn         = {{1096-9071}},
  keywords     = {{longitudinal cohort study; cervical cancer; PCR}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1169--1175}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Journal of Medical Virology}},
  title        = {{Population-based study of screening test performance indices of three human papillomavirus DNA tests}},
  url          = {{http://dx.doi.org/10.1002/jmv.20898}},
  doi          = {{10.1002/jmv.20898}},
  volume       = {{79}},
  year         = {{2007}},
}